menu search

SPPI / Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program. Read More
Posted: Nov 28 2022, 13:32
Author Name: Zacks Investment Research
Views: 092122

SPPI News  

Spectrum's Rolvedon A Differentiator In A $3B/Yr Market

By Seeking Alpha
June 22, 2023

Spectrum's Rolvedon A Differentiator In A $3B/Yr Market

Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Spectrum's ROLVEDON more_horizontal

Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 9, 2023

Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates

Spectrum Pharmaceuticals (SPPI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compare more_horizontal

Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?

By InvestorPlace
April 25, 2023

Why Is Spectrum Pharmaceuticals (SPPI) Stock Up 35% Today?

Spectrum Pharmaceuticals (NASDAQ: SPPI ) stock is soaring higher on Tuesday thanks to an acquisition deal with Assertio (NASDAQ: ASRT ). This deal w more_horizontal

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 22, 2023

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2022 Earnings Call Transcript

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI ) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET Company Participants Thomas Riga - President more_horizontal

Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

By Business Wire
March 17, 2023

Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies more_horizontal

Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

By Zacks Investment Research
November 28, 2022

Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program. more_horizontal

Penny Stocks To Buy: The Good, Bad, & Ugly & 3 To Watch Now

By PennyStocks
September 9, 2022

Penny Stocks To Buy: The Good, Bad, & Ugly & 3 To Watch Now

Whether you're a seasoned trader making money with penny stocks or just more_horizontal

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Thomas Riga on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 11, 2022

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Thomas Riga on Q2 2022 Results - Earnings Call Transcript

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Michael Grabow - SVP, C more_horizontal


Search within

Pages Search Results: